Litcius/Paper detail

The case for an HIV cure and how to get there

Mark Dybul, Timothy Attoye, Solange Baptiste, Peter Cherutich, François Dabis, Steven G. Deeks, Carl W. Dieffenbach, Brian Doehle, Maureen M. Goodenow, Adam Jiang, Dominic Kemps, Sharon R. Lewin, Murray Lumpkin, Lauren Mathae, Joseph M. McCune, Thumbi Ndung’u, Moses Supercharger Nsubuga, Holly L. Peay, John C. Pottage, Mitchell Warren, Izukanji Sikazwe

2020The Lancet HIV104 citationsDOIOpen Access PDF

Abstract

In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.

Topics & Concepts

General partnershipMedicineHuman immunodeficiency virus (HIV)ModalitiesBusinessStakeholderStigma (botany)Public relationsPolitical scienceFamily medicineSociologyFinancePsychiatrySocial scienceHIV/AIDS Research and InterventionsHIV Research and TreatmentHIV, Drug Use, Sexual Risk
The case for an HIV cure and how to get there | Litcius